Identifying the mechanisms underlying the regulation of immune checkpoint molecules and
the therapeutic impact of targeting them in cancer is critical. Here we show that high …

Despite advancements in targeting the immune checkpoints program cell death protein 1
(PD-1), programmed death ligand 1 (PD-L1), and cytotoxic T lymphocyte–associated protein …

Targeting the anti-tumor immune response via the B7 family of immune-regulatory
checkpoint proteins has revolutionized cancer treatment and resulted in punctuated …

Checkpoint immunotherapy has yielded meaningful responses across many cancers but
has shown modest efficacy in advanced prostate cancer. B7 homolog 3 protein (B7 …

Abstract Development of resistance to chemotherapy is a major obstacle in extending the
survival of patients with cancer. Although originally defined as an immune checkpoint …

Therapeutic blockade of the immune checkpoint proteins programmed cell death protein 1
(PD-1) and cytotoxic T lymphocyte antigen 4 (CTLA4) has transformed cancer treatment …

Despite widespread utilization of immunotherapy, treating immune-cold tumors has proved
to be a challenge. Here, we report that expression of the immune checkpoint molecule B7 …

Immune checkpoint molecules, including inhibitory and stimulatory immune checkpoint
molecules, are defined as ligand–receptor pairs that exert inhibitory or stimulatory effects on …

The role of B cells in anti-tumour immunity is still debated and, accordingly,
immunotherapies have focused on targeting T and natural killer cells to inhibit tumour …

Immunotherapy for cancer is a rapidly developing treatment that modifies the immune
system and enhances the antitumor immune response. B7-H3 (CD276), a member of the B7 …